Σύγκριση μεθόδων

	Δοκιμασία Διαπερατότητας Κυττάρων Caco-2	Συντελεστής Ομοιότητας Διάλυσης f1/f2	Φαρμακομεταφορείς λιποσωμάτων
Πεδίο	Φαρμακολογία	Φαρμακολογία	Φαρμακολογία
Οικογένεια	Process / pipeline	Process / pipeline	Process / pipeline
Έτος προέλευσης	1989	1996	1965
Δημιουργός	Ingrid Hidalgo	James Moore and Hector Flanner	Alec Bangham
Τύπος	absorption screening	similarity testing	formulation technology
Θεμελιώδης πηγή	Hidalgo, I. J., Raub, T. J., & Borchardt, R. T. (1989). Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology, 96(3), 736-749.	Moore, J. W., & Flanner, H. H. (1996). Mathematical comparison of dissolution profiles. Pharmaceutical Technology, 20(6), 64-74.	Bangham, A. D., Standish, M. M., & Watkins, J. C. (1965). Diffusion of univalent ions across the lamellae of swollen phospholipid films and the determination of membrane potential. Journal of Molecular Biology, 13(1), 238-252.
Εναλλακτικές ονομασίες	Caco-2 assay, intestinal permeability, ADME screening	f1, f2, similarity factor	liposomal formulation, vesicular delivery, lipid nanoparticles
Συναφείς	3	3	3
Σύνοψη	The Caco-2 assay is an in vitro model system using human colon carcinoma cell monolayers to screen drug intestinal permeability. Developed by Hidalgo and colleagues in 1989, Caco-2 cells differentiate into an epithelial barrier resembling intestinal mucosa, enabling rapid assessment of drug absorption potential and identification of transporter-mediated transport.	The f1 and f2 factors are dimensionless statistical measures developed by Moore and Flanner to quantify the similarity between two dissolution profiles. Adopted by regulatory agencies (FDA, EMA) as the gold standard for comparing dissolution curves, these factors enable rapid assessment of whether formulation changes significantly impact drug release.	Liposomal encapsulation is a formulation technique using lipid bilayer vesicles (liposomes) to enclose drugs, improving bioavailability, reducing toxicity, and enabling targeted delivery. Developed by Alec Bangham in 1965, liposomes are now standard in pharmaceutical development, with several FDA-approved liposomal drugs on the market.